Arca
Skip to content

EGLN3: Prolyl hydroxylase EGLN3

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Prolyl hydroxylase that mediates hydroxylation of proline residues in target proteins, such as PKM, TELO2, ATF4, GPX4 and HIF1A.

  • Drugs that act on it: 2
  • With a US drug page: 1
  • Type: Protein

Drugs That Act on It

Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page
VadadustatApprovedEgl nine homolog 3 inhibitorInhibitorBoxed warning
Molidustat—Egl nine homolog 3 inhibitorInhibitor—

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Anemia
0.60
Chronic renal failure syndrome
0.37
Placenta praevia
0.36
Stage 5 chronic kidney disease
0.33
Abnormality of the skeletal system
0.32
Refractive error
0.30
Liver disorder
0.30
Placental abruption
0.29
Facial pain
0.28

Genes and Related Targets

Complexes and families that share a gene with this target
Genes
EGLN3

Drugs and mechanisms are from ChEMBL CHEMBL5705 (CC BY-SA 3.0). Gene name, function (UniProt Q9H6Z9, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.